$25.45 Million in Sales Expected for Nektar Therapeutics (NKTR) This Quarter

Equities research analysts expect Nektar Therapeutics (NASDAQ:NKTR) to post sales of $25.45 million for the current fiscal quarter, according to Zacks. Six analysts have made estimates for Nektar Therapeutics’ earnings, with the lowest sales estimate coming in at $24.10 million and the highest estimate coming in at $27.64 million. Nektar Therapeutics posted sales of $38.02 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 33.1%. The business is expected to report its next quarterly earnings report on Thursday, May 9th.

According to Zacks, analysts expect that Nektar Therapeutics will report full year sales of $109.43 million for the current year, with estimates ranging from $101.19 million to $127.00 million. For the next fiscal year, analysts expect that the company will report sales of $221.92 million, with estimates ranging from $117.62 million to $423.92 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that that provide coverage for Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.13. Nektar Therapeutics had a return on equity of 50.22% and a net margin of 57.09%. The company had revenue of $39.83 million for the quarter, compared to the consensus estimate of $25.97 million. During the same quarter last year, the company earned ($0.21) earnings per share.

A number of brokerages recently weighed in on NKTR. BidaskClub raised Nektar Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, April 5th. Zacks Investment Research raised Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a research report on Tuesday, January 8th. BMO Capital Markets began coverage on Nektar Therapeutics in a research report on Friday, February 22nd. They set an “outperform” rating and a $75.00 price objective on the stock. ValuEngine downgraded Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 21st. Finally, Svb Leerink began coverage on Nektar Therapeutics in a research report on Friday, March 15th. They set a “mkt perform” rating and a $38.00 price objective on the stock. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $73.92.

In other Nektar Therapeutics news, COO John Nicholson sold 63,000 shares of the stock in a transaction dated Monday, January 28th. The stock was sold at an average price of $42.82, for a total value of $2,697,660.00. Following the completion of the sale, the chief operating officer now directly owns 237,477 shares in the company, valued at $10,168,765.14. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Maninder Hora sold 2,386 shares of the stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $42.39, for a total value of $101,142.54. Following the completion of the sale, the senior vice president now owns 99,374 shares of the company’s stock, valued at $4,212,463.86. The disclosure for this sale can be found here. Over the last quarter, insiders sold 241,824 shares of company stock valued at $10,249,993. 4.31% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in NKTR. FMR LLC raised its stake in Nektar Therapeutics by 8.5% in the fourth quarter. FMR LLC now owns 25,961,520 shares of the biopharmaceutical company’s stock valued at $853,355,000 after buying an additional 2,041,954 shares during the last quarter. Norges Bank purchased a new stake in Nektar Therapeutics in the fourth quarter valued at about $63,723,000. Vanguard Group Inc raised its stake in Nektar Therapeutics by 3.6% in the third quarter. Vanguard Group Inc now owns 18,922,650 shares of the biopharmaceutical company’s stock valued at $1,153,525,000 after buying an additional 660,907 shares during the last quarter. Deutsche Bank AG raised its stake in Nektar Therapeutics by 131.6% in the fourth quarter. Deutsche Bank AG now owns 947,004 shares of the biopharmaceutical company’s stock valued at $31,125,000 after buying an additional 538,170 shares during the last quarter. Finally, BB Biotech AG raised its stake in Nektar Therapeutics by 63.4% in the fourth quarter. BB Biotech AG now owns 1,380,975 shares of the biopharmaceutical company’s stock valued at $45,393,000 after buying an additional 535,975 shares during the last quarter. Institutional investors own 94.62% of the company’s stock.

Shares of NKTR stock opened at $35.15 on Friday. Nektar Therapeutics has a 1-year low of $29.22 and a 1-year high of $104.88. The stock has a market cap of $6.22 billion, a P/E ratio of 9.30 and a beta of 3.05. The company has a debt-to-equity ratio of 0.14, a quick ratio of 17.39 and a current ratio of 17.53.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

See Also: What is a Reverse Stock Split?

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.